Effects of Cannabidiol and Beta-Caryophyllene Alone or in Combination in a Mouse Model of Permanent Ischemia
Current treatments for stroke, which account for 6.5 million global deaths annually, remain insufficient for treatment of disability and mortality. One targetable hallmark of stroke is the inflammatory response following infarct, which leads to significant damage post-infarct. Cannabinoids and their...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/6/2866 |
id |
doaj-ec7058fe3faf45ada10f1d3bb912c37f |
---|---|
record_format |
Article |
spelling |
doaj-ec7058fe3faf45ada10f1d3bb912c37f2021-03-12T00:06:18ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-03-01222866286610.3390/ijms22062866Effects of Cannabidiol and Beta-Caryophyllene Alone or in Combination in a Mouse Model of Permanent IschemiaCody G. Yokubaitis0Hassan N. Jessani1Hongbo Li2Allison K. Amodea3Sara Jane Ward4Center for Substance Abuse Research, Department of Pharmacology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA Center for Substance Abuse Research, Department of Pharmacology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA Center for Substance Abuse Research, Department of Pharmacology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA Center for Substance Abuse Research, Department of Pharmacology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA Center for Substance Abuse Research, Department of Pharmacology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA Current treatments for stroke, which account for 6.5 million global deaths annually, remain insufficient for treatment of disability and mortality. One targetable hallmark of stroke is the inflammatory response following infarct, which leads to significant damage post-infarct. Cannabinoids and their endogenous targets within the CNS have emerged as potential treatments for neuroinflammatory indications. We and others have previously shown that synthetic agonists of the cannabinoid CB2 receptor reduce infarct size and microglial activation in rodent models of stroke. The non-cannabinoid receptor mediated effects of the phytocannabinoid cannabidiol (CBD) have also shown effectiveness in these models. The present aim was to determine the single and combined effects of the cannabis-derived sesquiterpene and putative CB2 receptor agonist β-caryophyllene (BCP) and CBD on permanent ischemia without reperfusion using a mouse model of photothrombosis. Because BCP and CBD likely work through different sites of action but share common mechanisms of action, we sought to determine whether combinations of BCP and CBD were more potent than either compound alone. Therefore we determined the effect of BCP (3–30 mg/kg IP) and CBD (3–30 mg/kg IP), given alone or in combination (30:3, 30:10, and 30:30 BCP:CBD), on infarct size, microglial activation, and motor performance.https://www.mdpi.com/1422-0067/22/6/2866strokecannabidiolbeta-caryophyllenemicrogliaphotothrombosiscannabinoid CB2 receptor |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Cody G. Yokubaitis Hassan N. Jessani Hongbo Li Allison K. Amodea Sara Jane Ward |
spellingShingle |
Cody G. Yokubaitis Hassan N. Jessani Hongbo Li Allison K. Amodea Sara Jane Ward Effects of Cannabidiol and Beta-Caryophyllene Alone or in Combination in a Mouse Model of Permanent Ischemia International Journal of Molecular Sciences stroke cannabidiol beta-caryophyllene microglia photothrombosis cannabinoid CB2 receptor |
author_facet |
Cody G. Yokubaitis Hassan N. Jessani Hongbo Li Allison K. Amodea Sara Jane Ward |
author_sort |
Cody G. Yokubaitis |
title |
Effects of Cannabidiol and Beta-Caryophyllene Alone or in Combination in a Mouse Model of Permanent Ischemia |
title_short |
Effects of Cannabidiol and Beta-Caryophyllene Alone or in Combination in a Mouse Model of Permanent Ischemia |
title_full |
Effects of Cannabidiol and Beta-Caryophyllene Alone or in Combination in a Mouse Model of Permanent Ischemia |
title_fullStr |
Effects of Cannabidiol and Beta-Caryophyllene Alone or in Combination in a Mouse Model of Permanent Ischemia |
title_full_unstemmed |
Effects of Cannabidiol and Beta-Caryophyllene Alone or in Combination in a Mouse Model of Permanent Ischemia |
title_sort |
effects of cannabidiol and beta-caryophyllene alone or in combination in a mouse model of permanent ischemia |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1661-6596 1422-0067 |
publishDate |
2021-03-01 |
description |
Current treatments for stroke, which account for 6.5 million global deaths annually, remain insufficient for treatment of disability and mortality. One targetable hallmark of stroke is the inflammatory response following infarct, which leads to significant damage post-infarct. Cannabinoids and their endogenous targets within the CNS have emerged as potential treatments for neuroinflammatory indications. We and others have previously shown that synthetic agonists of the cannabinoid CB2 receptor reduce infarct size and microglial activation in rodent models of stroke. The non-cannabinoid receptor mediated effects of the phytocannabinoid cannabidiol (CBD) have also shown effectiveness in these models. The present aim was to determine the single and combined effects of the cannabis-derived sesquiterpene and putative CB2 receptor agonist β-caryophyllene (BCP) and CBD on permanent ischemia without reperfusion using a mouse model of photothrombosis. Because BCP and CBD likely work through different sites of action but share common mechanisms of action, we sought to determine whether combinations of BCP and CBD were more potent than either compound alone. Therefore we determined the effect of BCP (3–30 mg/kg IP) and CBD (3–30 mg/kg IP), given alone or in combination (30:3, 30:10, and 30:30 BCP:CBD), on infarct size, microglial activation, and motor performance. |
topic |
stroke cannabidiol beta-caryophyllene microglia photothrombosis cannabinoid CB2 receptor |
url |
https://www.mdpi.com/1422-0067/22/6/2866 |
work_keys_str_mv |
AT codygyokubaitis effectsofcannabidiolandbetacaryophyllenealoneorincombinationinamousemodelofpermanentischemia AT hassannjessani effectsofcannabidiolandbetacaryophyllenealoneorincombinationinamousemodelofpermanentischemia AT hongboli effectsofcannabidiolandbetacaryophyllenealoneorincombinationinamousemodelofpermanentischemia AT allisonkamodea effectsofcannabidiolandbetacaryophyllenealoneorincombinationinamousemodelofpermanentischemia AT sarajaneward effectsofcannabidiolandbetacaryophyllenealoneorincombinationinamousemodelofpermanentischemia |
_version_ |
1724223334276661248 |